Treated Colorectal Cancer: What is the Cost to Primary Care?

• Main Authors: D.A.L. Macafee, J. West, J.H. Scholefield, D.K. Whynes
• Format: Article
• Language: English
• Published: SAGE Publishing 2009-01-01
• Series: Clinical Medicine Insights: Oncology
• Online Access: https://doi.org/10.4137/CMO.S877

Background Colorectal cancer is the second commonest cause of cancer death and the cost to primary care has not been estimated. Aim To determine the direct primary care costs of colorectal cancer care. Design Retrospective case note review. Setting Nottingham, United Kingdom. Methods We identified people with colorectal cancer between 1995 and 1998, from computerised pathology records. Colorectal cancer related resources consumed in primary care, from hospital discharge to death, were identified from retrospective notes review. Outcome measures were costs incurred by the General Practitioner (GP) and the total cost to primary care. We used multiple linear regression to identify predictors of cost. Results Of 416 people identified from pathology records, the median age at primary operation of the 135 (33%) people we selected was 74.2 (IQR 14.4) years, 75 (56%) were male. The median GP cost was: Dukes A £61.0 (IQR 516.2) and Dukes D £936.2 (1196.2) p < 0.01. The geometric mean ratio found Dukes D cancers to be 10 times as costly as Dukes A. The median total cost was: Dukes A £1038.3 (IQR 5090.6) and Dukes D £1815.2 (2092.5) p = 0.06. Using multivariate analysis, Dukes stage was the most important predictor of GP costs. For total costs, the presence of a permanent stoma was the most predictive variable, followed by adjuvant therapy and advanced Dukes stage (Dukes C and D). Conclusions Contrary to hospital based care costs, late stage disease (Dukes D) costs substantially more to general practice than any other stage. Stoma care products are the most costly prescribable item. Costs savings may be realised in primary care by screening detection of early stage colorectal cancers.